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Objective:
 
 The aim of this study was to translate the
Psoriasis Disability Index (PDI) into Norwegian and
validate it in a Norwegian setting. The PDI is a measure
that was developed to assess the impact of psoriasis on
the patient’s life.
 
Methods:
 
 Two hundred and eighty-two patients with
psoriasis were included in the study (80% outpatients,
and 20% hospitalized). 
 
Results:
 
 Face and content validity were assessed as sat-
isfactory. The PDI seems to capture issues of impor-
tance to patients. The results indicate that the PDI does
not capture a unidimensional concept. A factor analysis
(principal component with orthogonal rotation) re-
sulted in three factors (physical, social, and hygienic)
that were substantially different. All three factors had
satisfactory internal consistency. Altogether they ex-
plained 58% of the variance. In addition, there were
differing patterns of correlations with external criteria,
such as dimensions of SF-36, as well as with sex, age,
and education.
 
Conclusions:
 
 The PDI has been found to have accept-
able reliability in this study. However, further valida-
tion is necessary to estimate the sensitivity to change.
 
Introduction
 
Living with a chronic skin disease such as psoria-
sis poses problems for the individuals concerned
with regard to daily living and functioning [1–3].
Studies also show that patients with psoriasis rate
their general health lower than the general popu-
lation [4].
It is important to have valid measures of the
concept of disability. Disability can be understood
as any restriction or lack of ability to perform an
activity in the manner or within the range consid-
ered normal for a human being [5]. The reduction
of disability due to chronic diseases is one of the
main targets of the World Health Organization
for health policy in Europe [6].
Several different methods are available that can
be used to describe the burden of illness or the im-
pact on health-related quality of life issues. It is
common for investigators to use traditional health
status measurement scales to measure health as-
pects of quality of life. However, the relevance of
the domains in generic health status measures var-
ies according to the disease groups studied. Atten-
tion is now being paid to disease-specific measures
of quality of life which attempt to tap domains
that are relevant to people with specific condi-
tions. The study by Bowling [7] has confirmed
that the effects of illness on quality of life differ
with the patient group and support the trend of
developing disease-specific questionnaires in addi-
tion to generic scales.
The Psoriasis Disability Index (PDI) is a dis-
ease-specific questionnaire measuring disability in-
duced by psoriasis [8]. The PDI is a well-known
psoriasis disability measure and has been used in
several studies to assess the burden of living with
psoriasis, or the effects of different treatments, on
patient experience of disability [9–15]. The ques-
tionnaire was developed as a multidimensional
measure related to the impact of psoriasis [8].
The aim of this paper is to report on the valid-
ity and reliability tests concerning the Norwegian
version of the Psoriasis Disability Index (PDI) for
use with Norwegian psoriasis patients. The fol-
lowing questions were asked in this respect:
1. Are the face and content validity acceptable?
2. Do the different subscales of the PDI merit suf-
ficient empirical support in a Norwegian sam-
ple of psoriasis patients (construct validity)?
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3. Are the internal consistency of the PDI and its
putative subscales satisfactory?
4. Does the PDI show discriminative power (con-
struct validity)?
 
Methods
 
Subjects
 
The sample comprised consecutive inpatients and
outpatients treated in three dermatology depart-
ments in the eastern part of Norway. Three hun-
dred thirty-four patients were asked to participate
in the study. Out of these, 22 patients did not
want to participate. Further, 21 patients were ex-
cluded because they did not return the question-
naires, and another 9 were excluded because of
various problems in completing the questionnaires.
Hence, 282 patients completed the testing, yielding
a response rate of 85%. Patients filled in the ques-
tionnaires at home (except for the hospitalized pa-
tients) and sent them back to the researcher. An
ethics committee approved the study.
 
Measures
 
The following measures were used; The Psoriasis
Disability Index (PDI), the Quality of Life Scale
(QOLS), and the SF-36. In addition, the degree of
physical symptoms specific to psoriasis and sleep-
ing problems were assessed. The QOLS, the SF-36,
physical symptoms, and sleeping problems were in-
cluded to assess aspects of the discriminative power
of the PDI. It is quite clear that disease-specific
disability, physical symptoms, health status, and
overall quality of life are related to each other.
However, they are not the same. One could as-
sume that these variables would correlate to a cer-
tain extent.
Furthermore, demographic variables such as age,
gender, marital status, education, and cohabitation,
and clinical variables such as hospital setting (in/
outpatients), self-reported arthritis complications
(1 item), other chronic diseases (1 item), disease
duration, and previous hospitalization, were re-
ported.
 
Disease-specific Disability: The Psoriasis Dis-
ability Index.
 
Comprising 15 questions, the PDI
was developed by Finlay and concerns the impact
of psoriasis on daily activities, work, personal re-
lationships, leisure, and treatment. Respondents
consider the past four weeks, rating questions on a
7-point linear analogue scale on which “0” indi-
cates no disability and “6” represents maximum
disability. An overall index of disability is derived,
representing the sum of all answers, with scores
ranging from 0 to 90. The higher the score, the
greater the disability [8,9].
The PDI was translated into Norwegian follow-
ing criteria of translation procedure [16]. First, two
independent English-speaking translators translated
the questionnaire from English to Norwegian. Af-
ter an assessment of the Norwegian versions, these
were combined into one version by the first author
in agreement with the translators. There were only
minor discrepancies between the two versions.
Thereafter, two other independent translators back-
translated the Norwegian version. The author of the
instrument approved the version.
 
Physical Symptoms Specific to Psoriasis.
 
Self-
reported symptoms were assessed in five questions
drawn from the literature, concerning symptoms
such as itching, burning, scaling, and suppuration,
stinging pain and pain in the joints. The response
alternatives ranged from no symptoms at all (scored
1) to serious symptoms (scored 7).
 
Sleep.
 
Sleeping problems were assessed in ques-
tions that asked whether the patients experienced
their sleep as fitful, had trouble falling asleep, or
woke up during their sleeping hours, and how
much time it usually took to fall asleep. The index
scores ranged from 1 (indicating severe sleeping
problems) to 6 (indicating no sleeping problems).
 
Health Status.
 
The SF-36 is one of several gen-
eral health status questionnaires developed in the
United States by the Medical Outcomes Study
(MOS) investigators. It consists of 36 questions on
self-reported aspects of health. The instrument in-
cludes the following domains: self-reported general
health, physical functioning, mental health, bodily
pain, role limitations-physical, role limitations-emo-
tional, vitality, social functioning and change in
health in the past year. These domains may be
combined to form physical and mental health
composite scores. The scores are transferred into a
scale ranging from 0 to 100. The higher score, the
better health. This tool has shown satisfactory re-
liability and validity, and it has been thoroughly
tested for psychometric properties in several coun-
tries, including Norway [17–20].
 
Overall Quality of Life.
 
The Quality of Life
Scale (QOLS) is a 16-item, domain-specific instru-
ment adapted by Burckhardt et al. [21,22] for use
with patients who have chronic diseases. The
questionnaire was developed empirically in the
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United States by asking people about their quality
of life. Rather than employing a theory or model,
it explores factors such as physical and material
well being, personal development, relationships
with others, participation in social, community,
and civic activities, and recreation. The question-
naire was developed for a healthy population, then
adapted to patients suffering from chronic condi-
tions. Patients were asked to rate their present level
of satisfaction with the above-mentioned factors
on a 7-point scale called the Delighted–Terrible
Scale. The questionnaire is scored by adding up
the items to obtain a total score (min. 16 – max.
112). The higher score, the better the quality of life.
The QOLS has been validated for use with Nor-
wegian psoriasis patients [23].
 
Statistics
 
The statistical software SPSS PC for Windows
(version 7.5) was used in the statistical analyses.
Descriptive analyses were performed to assess the
frequency, mean (raw and percentage), standard
deviation, and range of the scores. Cronbach’s al-
pha was used to estimate the internal consistency
of the scale. A principal component analysis with
varimax rotation was performed to assess the em-
pirical support of the PDI in a Norwegian sample
of patients. Further, correlation coefficient (Pear-
son’s 
 
r
 
), and multiple regression analyses (linear)
were used to explore the discriminative power of
the PDI. Missing data were handled by giving a
missing item the mean score for that item in the
total sample if fewer than 40% of the items were
missing. Substituting the mean of the completed
items in the subscale when more than 50% are
completed is generally the most unbiased and pre-
cise approach to missing data [24].
 
Results
 
Face and Content Validity of the PDI
 
Two experts on quality of life in the nursing field
and three dermatology nurses assessed the face
and content validity of the PDI. Both the experts
on the concept of quality of life and the nurses
working with the patient group found the instru-
ment to cover important aspects of the impact of
living with a disease such as psoriasis. In addition,
a sample of 15 patients rated the questionnaire to
further secure face validity. This pilot sample was
asked to fill in the questionnaire and indicate
whether they found the questions relevant to their
life situation and easy to answer. None of the pa-
tients had difficulty understanding the questions
or filling out the responses. They also found the
questions relevant to their life situation. There-
fore, no corrections or changes were made as a re-
sult of these assessments.
 
Descriptive Information
 
The demographic and clinical characteristics of
the study sample are shown in Table 1. Eighty
percent were attending the outpatient clinics, and
20% were hospitalized. The total mean symptom
score was 14.8 (SD 5.8, range 5–33). The patients
reported highest score in scaling (mean 3.8, SD
1.6, range 1–7), whereas the patients reported the
lowest score with regard to suppuration (mean 1.8,
SD 1.4, range 1–7). Further information about the
clinical characteristics is shown in Table 1.
The Kolmogorov-Smirnov Test of normality
showed that the PDI in the sample was not nor-
mally distributed (
 
p
 
 
 

 
 .000). The mean total score
was 27.7 (SD 19.6, range 0–84). The percentage
score was estimated to be 32.9 (SD 23.3). The en-
dorsement frequencies (i.e., less than 85% of re-
spondents providing the same response for each
item) for individual items were acceptable in most
of the items, except for items 8a and 8b (career af-
fected) and item 13 (unable to use, criticized or
stopped from using communal bathing or chang-
ing facilities). Respectively, 90, 89, and 87% of
 
Table 1
 
Demographic and clinical characteristics of the 
sample (N 
 

 
 282)
 
Characteristics N 
 

 
 282
Age in years mean (SD) 46.5 (15.4)
Age groups (%)
19–39 years 39.3
40–59 years 37.2
60 and more 23.4
Gender (male) (%) 56.7
Marital status: married (%) 49
Educational status (%)
One or two years at upper secondary school or less 63.8
Polytechnic or university less than 4 years 27.4
Polytechnic or university 4 years or more 8.1
Work: employed (%) 50.7
Hospital setting at present (%)
Hospitalized 20.2
Out-patient clinic 79.8
Arthritis complications: yes (%) 28.0
Other chronic conditions (%) 42.6
Family history of psoriasis (%) 58.2
Hospitalized because of psoriasis the last five years (%)
1–2 times 21.3
3–4 times 6.8
5 times and more 7.3
Disease duration in years mean (SD) 18.7 (14.3)
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the respondents provided “not at all” as a re-
sponse.
The two most affected areas were the daily ac-
tivities and treatment domains. The least affected
area was work or school for those patients who
were employed or attended school. Further de-
scriptive information concerning the Psoriasis Dis-
ability Index (PDI) is presented in Table 2.
 
Construct Validity
 
Empirical Support for the PDI Indexes.
 
The
construct validity of the PDI was analyzed by
means of principal component analyses with or-
thogonal rotation. The item alternatives 6, 7, and
8 in the questionnaire were combined into one ad-
ditive index before factor-analyzing the instru-
ment. The principal component analyses using an
eigenvalue of 
 

 
1.0 as the criterion resulted in a
three-factor solution. The scree plot showed a
sharp drop in the percentage of variance explained
between the third and fourth factor (Fig. 1). A
three-factor solution was accepted as the best one
and was applied to the data. The loading of the
PDI items on the three factors is shown in Table 3.
Thirteen of the original 15 items remained when
the criterion of highest loading was used, above
0.35 and at least 0.10 stronger than the next but
highest loading. Item 8 (career affected) and item
11 (stopped going out socially or to any special
functions) did not fulfill the inclusion criteria. The
factors could be labeled as follows:
1. Physical disability (5 items) such as “interfered
with carrying out work around the house or
garden;”
2. Social disability (4 items) such as “problems
with partner or any of your close friends or rel-
atives;”
3. Hygienic disability (4 items) such as “worn dif-
ferent types or colors of clothes because of pso-
riasis.”
The factor solution explained 58% of the total
variance in the 15-item PDI. The first author la-
beled the factors according to the themes of the
items. Cronbach’s alphas ranged from 0.67 in the
social index to 0.88 in the total index (see Table
3). Correlation between the three new additive in-
dexes ranged from 0.54 to 0.45. The highest cor-
relation was found between the physical and hy-
gienic indexes. The lowest correlation was found
between hygienic and social indexes. Table 3 shows
that the squared multiple correlation for each item
within each factor ranged from 0.07 to 0.74. In
the hygienic factor the lowest correlations were
found in item 4 (problem at hairdressers) and in item
 
Table 2
 
Descriptive information (mean, SD, range and percentage score) of the PDI items, and Cronbachs’ alpha of the 
subscales and total scale (N 
 

 
 282)
 
Mean (SD) Range Percentagescore (SD)
Cronbachs’
alpha
PDI total scale 27.7 (19.6) 0–84 32.9 (23.3) 0.87
Daily activities 12.9 (7.73) 0–30 43.0 (25.8) 0.75
1. Interfered with carrying out work around the house or garden 1.9 (2.2) 0–6
2. Wore different types or colors of clothes because of psoriasis 2.6 (2.3) 0–6
3. Changed or washed clothes 3.3 (2.2) 0–6
4. Problem at hairdressers 1.7 (2.0) 0–6
5. Had to take more baths than usual 1.8 (1.9) 0–6
Work or school 2.0 (3.9) 0–18 11.0 (21.7) 0.76
6. Lost time from work or school 0.9 (1.8) 0–6
7. Prevented doing things at work or school 0.7 (1.6) 0–6
8. Career affected 0.4 (1.3) 0–6
Alternative questions if not at work or school 2.8 (4.8) 0–18 15.5 (26.7) 0.84
6. Prevented carrying out normal daily activities 1.2 (2.0) 0–6
7. Altered the way in which normal daily activities carried out 1.1 (1.6) 0–6
8. Career affected 0.5 (1.5) 0–6
Personal relationships 2.3 (3.5) 0–12 19.2 (29.2) 0.77
9. Sexual difficulties 1.3 (2.1) 0–6
10. Problems with partner or any close friends or relatives 1.0 (1.7) 0–6
Leisure 6.0 (5.8) 0–24 25.0 (24.2) 0.69
11. Stopped going out socially or to any special functions 2.0 (2.2) 0–6
12. Difficulty doing any sport 2.5 (2.4) 0–6
13. Unable to use, criticised or stopped from using communal
bathing or changing facilities
0.6 (1.7) 0–6
14. Smoking or drinking alcohol more than normal 0.9 (1.7) 0–6
Treatment 0–6 30 (31.7)
15. Treatment made home messy or untidy 1.8 (1.9) 0–6
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2 (worn different types or colors of clothes be-
cause of psoriasis), in the social factor item 13
(unable to use, criticized or stopped from using
communal bathing or changing facilities) and in
item 14 (smoking or drinking alcohol more than
normally). With regard to the physical factor, the
lowest correlations were found in item 12 (diffi-
cult to do any sport) and in item 15 (treatment
made your home messy or untidy). None of the
squared multiple correlations were above 0.80.
 
The Discriminative Power of the PDI.
 
The corre-
lation coefficients between the PDI and the measures
of general health status, self-reported symptoms,
sleeping problems, hospital setting, and overall qual-
ity of life are shown in Table 4. The results showed
that the PDI correlated significantly with all vari-
ables in the correlation matrix. Patients who were
hospitalized, and patients who reported poorer glo-
bal quality of life and health, more physical symp-
toms, and sleeping problems also reported more
disability due to the impact of psoriasis.
Results from linear regression analyses, where
we looked for interactions, showed main effects
(negative) due to education on total disability and
in all subdimensions (physical, social, hygienic),
indicating that patients with less education report
more disability in total and in the subdimensions.
Age showed a negative effect on total disability
and in the social domain, indicating that younger
patients reported more disability both in total and
in the social subdomain. A negative effect was seen
for sex in the hygienic dimension, indicating that
women reported more hygienic disability. As to in-
teractions, age and gender showed negative interac-
tion effects in the hygienic dimension. These results
Figure 1 Scree plot of the factor analyses of the PDI.
Table 3 Factor loadings (rotated component matrix) and squared multiple correlations of the PDI items
 
Factor I
(Physical)
Factor II 
(Social)
Factor III
(Hygienic)
Squared 
Multiple
Correlation
Daily activities
1. Interfered with work around the house or garden 0.84* 0.10 0.12 0.61
2. Wore different types or colours of clothes because of psoriasis 0.26 0.28 0.55* 0.26
3. Changed or washed clothes 0.34 0.20 0.72* 0.50
4. Problem at hairdressers 0.00 0.00 0.75* 0.20
5. Had to take more baths than usual 0.26 0.10 0.76* 0.46
Work or school/Alternative questions if not at work or school
6. Lose time from work or school/prevented carrying out normal
daily activities 0.87* 0.00 0.15 0.68
7. Prevented from doing things at work or school/altered the way
in which normal daily activities carried out 0.86* 0.11 0.25 0.74
8. Career affected 0.43 0.34 0.00
Personal relationships
9. Sexual difficulties 0.10 0.83* 0.19 0.48
10. Problems with partner or any close friends or relatives 0.00 0.85* 0.00 0.43
Leisure
11. Stopped going out socially or to any special functions 0.50 0.37 0.44
12. Difficulty doing any sport 0.56* 0.39 0.21 0.31
13. Unable to use, criticized or stopped from using communal bathing
or changing facilities 0.16 0.39* 0.19 0.07
14. Smoking or drinking alcohol more than normal 0.35 0.48* 0.11 0.17
Treatment
15. Treatment made home messy or untidy 0.58* 0.33 0.30 0.38
Cronbachs’ alpha (total scale: 88) 0.87 0.67 0.75
 
*Factor
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indicate that younger patients and women report
more disability in the hygienic dimension. Interac-
tion effects were also found between age and edu-
cation in the physical dimension (Table 5). All inde-
pendent variables were centered before interaction
terms were created.
Interaction analyses also showed that when
correlation was estimated for three age groups
(less than 38, 38–54, more than 54), there was no
correlation between education and the physical
domain for the oldest patients, but results did
show a correlation between education and the so-
cial domain in the youngest group. Lastly, the cor-
relation between education and sex, on the one
hand, and the hygienic domain, on the other, was
much stronger for the oldest patients.
 
Discussion
 
As each specialty is asked to prove that their care
helps patients, it will become increasingly impor-
tant to assess the impact of psoriasis on the lives
of patients and the ways in which therapy and
care improve aspects of their quality of life [25].
In the present case, a British scale was adapted
for use with Norwegian psoriasis patients. Con-
ceptual, semantic, and linguistic divergence may
exist between cultures. Success in using a quality
of life measure such as the PDI requires a system-
atic approach to the translation and validation of
the measure [16]. The Norwegian version was
judged to have satisfactory face validity by nurses
in dermatology and by patients suffering from
psoriasis. The measure seems to capture important
aspects of the lives of psoriasis patients. Further,
the content validity was also acceptable from an
expert point of view.
Results from both the factor analyses and the
discriminative analyses showed that the PDI is not
a unidimensional instrument. Regarding the inter-
nal consistency of the original scale, the alpha co-
efficients were satisfactory, which indicates that
the scale is an internally consistent, additive in-
 
Table 4
 
Correlation coefficients (Pearson’s r) between the PDI, SF-36 dimensions, hospital setting, overall quality of life, and 
symptoms (N  272)
 
PDI total score
(high score 
 

 
more disability)
Physical
index
Social
index
Hygienic
index
Health status (high score
 
 
 
 better health)
Bodily pain
 

 
.58***
 

 
.62***
 

 
.34***
 

 
.36***
General health
 

 
.41***
 

 
.41***
 

 
.27***
 

 
.29***
Mental health
 

 
.52***
 

 
.46***
 

 
.45***
 

 
.36***
Physical functioning
 

 
.49***
 

 
.56***
 

 
.27***
 

 
.29***
Role limitation (emotional)
 

 
.49***
 

 
.52***
 

 
.34***
 

 
.30***
Role limitation (physical)
 

 
.57***
 

 
.63***
 

 
.32***
 

 
.36***
Social functioning
 

 
.59***
 

 
.53***
 

 
.50***
 

 
.41***
Vitality
 

 
.46***
 

 
.43***
 

 
.40***
 

 
.29***
Hospital setting .40*** .41*** .26*** .26***
Overall quality of life (high score
 
 
 
 better quality of life)
 

 
.39***
 

 
.36***
 

 
.36***
 

 
.20***
Symptoms (high score 
 

 
 more symptoms) .50*** .48*** .31*** .44***
Sleep (high score 
 

 
 less problems)
 

 
.53***
 

 
.46***
 

 
.39***
 

 
.46***
 
*** p 
 

 
 0.001
 
Table 5
 
Correlation coefficients (Pearsons r) and standardized beta weights (b) from multiple regression analyses between 
age, gender, education (main effects), age/gender, education/gender, education/age (interactions) (z-scores) and the PDI.
 
PDI total score Physical Social Hygienic
r b r b r b r b
Age
 

 
0.06
 

 
0.14*
 

 
0.04
 

 
0.11
 

 
0.14*
 

 
0.19** 0.04
 

 
0.01
Gender
 

 
0.03
 

 
0.04 0.01 0.01 0.00
 

 
0.01
 

 
0.13*
 

 
0.12*
Education
 

 
0.17**
 

 
0.22**
 

 
0.16**
 

 
0.23**
 

 
0.07
 

 
0.16*
 

 
0.14*
 

 
0.14*
Age/Gender
 

 
0.08
 

 
0.07
 

 
0.05
 

 
0.04 0.01 0.01
 

 
0.16**
 

 
0.13*
Education/Gender 0.02 0.04 0.02 0.05 0.04 0.09 0.03 0.01
Age/Education 0.02 0.09 0.07
 

 
0.12* 0.08 0.11
 
0.11 0.04
Adjusted P Square 0.04 0.03 0.03 0.03
* p  0.05, ** p  0.01
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strument in which scores (total score and subscale
scores) have meaning.
Three substantively different factors emerged in
the Principal Components Analyses. The pool of
items in the PDI allows us to create additive in-
dexes with satisfactory internal consistency (reli-
ability) and with intercorrelations between them-
selves that are only moderately strong. However,
three items showed a high endorsement frequency
and some of the item-factor squared multiple cor-
relations were low (indicating that they may mea-
sure a different construct). Therefore, one could
assume that some of these items could be re-
moved. This has to be further investigated. Before
items can be removed, the clinical importance of
these items has to be judged.
When developing the PDI, the items were
grouped into subscales based on common sense.
The PDI was not initially subjected to a factor
analysis. However, Kent and al Abadie [26] per-
formed a factor analysis on the 15-item version of
the PDI with 340 patients with psoriasis and pa-
tients with other skin diseases. Although most
items on the PDI were specific to psoriasis, some
items applied to other skin patient groups. A fac-
tor analysis of the items indicated that the PDI
contained two subscales, one concerning most as-
pects of everyday activities, the other concerning
specific public situations such as the use of com-
munal facilities. The differences in results from the
present factor analyses and the study by Kent and
al Abadie [26] could be due to differences in sam-
ple characteristics and methods used to investigate
the components within the instrument.
The discriminative power of the PDI was sup-
ported. Results showed differing patterns of corre-
lation with outside criteria such as the subdimen-
sions of SF-36, hospital setting, symptoms, quality
of life, as well as with sex, age, and education.
These correlations varied from one subdimension
in the PDI to another. The higher level of the PDI
scores (more disability) and the lower scores of the
SF-36 (less health) were reported. The highest cor-
relation was reported between the PDI and bodily
pain and social functioning health scales. Other
studies have found similar patterns. Root et al.
[12] found that patient-rated severity scores, gen-
eral health (GHQ), and disability (PDI) were cor-
related with each other. Finlay [9] found that
overall Sickness Impact Profile scores did not coin-
cide with clinical measures of psoriasis severity,
but were correlated with the PDI. In a study of
644 patients with mild to moderate psoriasis,
Nichol et al. [11] found that the PDI was best cor-
related with the social functioning scale in the SF-
36. Another study showed that the PDI score was
highly negatively correlated with all eight of the
SF-36 health domains (P  .0001 for each) [4].
Further, the results from the present study showed
that patients who reported a higher level of symp-
toms (physical impairment) also reported more
disability. Results from the study by Root et al.
[12] suggests that the impact of the disease will be
more closely related to the patient’s view of sever-
ity than the assessment of disease severity made by
doctors. From the patient’s point of view, it may
be more important to assess the disability effects
of the disease than its clinical severity and to insti-
tute treatments that are designed to alleviate the
social effects of their disease. The PDI also seems
to capture differences in age, gender, and educa-
tional status. Correlation with demographic vari-
ables do not only vary between PDI subdimensions,
but associations between the three subdimensions,
on the one hand, and sex and education, on the
other, are to some extent modified by age (i.e., there
are interaction effects).
Descriptive results on the original PDI showed
a mean percentage score of 32.9 (SD 23.3), which
may be seen as a moderate score. Most disability
was connected with daily activities and treatment
in this sample. Less disability was reported in the
work or school domain. A test of normality showed
that the PDI total score was significantly positively
skewed, which indicates that the lowest end (low
degree of disability) was most used, whereas one
would assume the opposite pattern because all the
patients were in a disease flare-up state. These re-
sults are in accordance with findings in other stud-
ies. In a study by Finlay and Coles [10] of the ef-
fect of severe psoriasis on the quality of life of 369
patients, the mean PDI percentage score was 38.2
(SD 23.3). The treatment section and the daily ac-
tivities scored highest, and the personal relationship
section scored lowest. In a sample of patients with
mild to moderate psoriasis, Nichol et al. [11] found
a percentage mean score of 16.59 (SD 16.23).
Conclusion
In summary, the Norwegian version of the PDI
has been found to have acceptable reliability and
validity for use in this group of Norwegian psoria-
sis patients. The measure also meets criteria such
as brevity, clarity, and ease of administration and
coding. The results indicate that the PDI does not
capture a unidimensional concept. A factor analy-
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sis resulted in three factors that were substantially
different. In addition, there were differing patterns
of correlations with external criteria. However,
the scale should be further tested in a sample of
patients with less impairment than those in this
study to examine the discriminative power of the
scale. Further validation within experimental de-
signs is necessary, before it can be claimed that the
instrument is sensitive to change.
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